ClinConnect ClinConnect Logo
Search / Trial NCT06703762

Efficacy of Photobiomodulation on Wound Healing and Il-6 in Neuropathic Foot Ulcer

Launched by CAIRO UNIVERSITY · Nov 21, 2024

Trial Information

Current as of August 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special type of light therapy, called Laser Photobiomodulation, on healing wounds known as neuropathic foot ulcers in people with type II diabetes. The researchers want to see if this therapy can help improve the healing process and reduce a specific marker in the body, called IL-6, which is linked to inflammation and healing.

To participate, you must have a diagnosed neuropathic foot ulcer that is between 6 and 12 square centimeters in size and meet certain health criteria, including being diagnosed with type II diabetes. Unfortunately, individuals with certain conditions, such as infections in the bone or severe illnesses requiring intensive care, as well as pregnant women and smokers, cannot participate. If you join the trial, you'll likely receive the light therapy and be monitored for how well your wound heals. This study is not yet open for recruitment, but it aims to gather important information that could help improve treatment options for diabetic foot ulcers in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All patient will be diagnosed with neuropathic foot ulcer.
  • All patient diagnosed as type II Diabetes Mellitus.
  • Wound size a 6-12 cm2.
  • Diabetic ulcers will be in grade 2 and 3 (Partial thickness skin loss involving epidermis and or dermis (superficial, abrasion, blister, and / or full thickness skin loss damage ore necrosis of subcutaneous tissue may extend down to but not through underlying fascia.
  • Exclusion Criteria:
  • Presence of osteomyelitis.
  • Patients associated with critical illness who needs intensive care.
  • Patients who suffer from cellulitis.
  • Patients who suffer from nerve injury.
  • Pregnancy.
  • Smokers
  • Malignant diseases
  • Use of immunosuppressive drugs
  • Phenytoin, cyclosporine, calcium channel blockers, etc.
  • Patients who not have burn or ulcer or trauma in this area

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Giza, , Egypt

Patients applied

0 patients applied

Trial Officials

Amal Mohamed Abd El-baky, PhD

Study Chair

Professor, Cairo university

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported